View PDF Version
 
DOI: 10.1039/A802350F (Paper) Reference Section for: J. Chem. Soc., Perkin Trans. 2, 1998, 1983-1992

Structure and dynamics of intercalation complexes of anthracyclines with d(CGATCG)2 and d(CGTACG)2. 2D-1H and 31P NMR investigations

(Note: The full text of this document is currently only available in the PDF Version )

Stefania Mazzini, Rosanna Mondelli and Enzio Ragg

Abstract

The interaction of (2S[hair space])-2-methoxymorpholinodoxorubicin 4 and morpholinodoxorubicin 5 with the hexanucleotides d(CGATCG)2 and d(CGTACG)2 has been studied by a combined use of 2D-1H and 31P NMR techniques and molecular dynamics (MD) calculations, in comparison with doxorubicin 1, daunorubicin 2 and idarubicin 3. Both 1H and 31P chemical shifts of imino protons and phosphates respectively have been shown to be a sensitive probe for the intercalation sites (two anthracycline molecules at the CpG sites). A relevant number of NOE interactions allowed the structure of the complexes in solution to be derived through restrained MD calculations, which were compared with those obtained by X-ray analysis. In all the complexes the aglycone was shown to be located in the middle of the double helix, orthogonally oriented with respect to the base pairs, with ring D extending out of the helix on the major groove and ring A, with 9H8 conformation, between guanines G2 and G12. The daunosamine and morpholino moieties lie in the center of the minor groove, with slightly different positions than in the X-ray structures. In all the complexes the daunosamine ring is located at the A3 (T3) level, while the morpholino ring displays NOE interactions with the fourth unit T4 (A4). The deformations of the double helix are revealed by an increased distance between protons of the C5 and G6 units and by conformational changes at the level of the α, ζ, ε and δ angles of the phosphoribose backbone. The variation of the 31P chemical shifts is interpreted in terms of conformational equilibria leading to different populations of conformers. This is clearly shown from the values of the α and ζ torsion angles, monitored during the MD, which indicate a relevant population of trans forms for ζ and also for α angles of C5pG6 and G2pT3 (G2pA3) units, while the other phosphates exist entirely in the α, ζ, gauche,gauche conformation. The dissociation rate constants were measured by 2D 31P NOESY-exchange experiments for 1 and 4. The decrease of koff for 4, corresponding to a ten-fold increase of the residence time of the drug in the intercalation sites, is in line with the higher activity found for methoxymorpholinodoxorubicin 4.

References

  1. (a) F. Arcamone, Doxorubicin: Anticancer Antibiotics, New York, Academic Press, 1981 Search PubMed; (b) S. Penco and F. Arcamone, Molecular aspects of anticancer drug action, ed. J. W. Lown, Macmillan Press, London, 1988 Search PubMed; (c) R. D. Anderson, M. L. Veigl, J. Baxter and W. D. Sedwick, Cancer Res., 1991, 51, 3930 CAS.
  2. (a) E. M. Acton, G. L. Tong, C. W. Mosher and R. L. Wolgemuth, J. Med. Chem., 1984, 27, 638 CrossRef CAS; (b) A. Bargiotti, P. Zini, S. Penco and F. Giuliani, US Pat., 4 672 057, 1987 Search PubMed; (c) N. Komeshima, H. Kawai, S. Nakajima, M. Watanabe, T. Tsurno, T. Takeuchi and N. Otake, J. Antibiot., 1989, 42, 1425.
  3. (a) J. Westendorf, M. Aydin, G. Groth, O. Weller and H. Marquardt, Cancer Res., 1989, 49, 5262 CAS; (b) M. Grandi, G. Pezzoni, D. Ballinari, L. Capolongo, A. Suarato, A. Bargiotti, D. Faiardi and F. Spreafico, Cancer Treat. Rev., 1990, 17, 133 CAS; (c) P. A. Vasey, D. Bisset, M. Strolin-Benedetti, I. Poggesi, M. Breda, L. Adams, P. Wilson, M. A. Pacciarini, S. B. Kaye and J. Cassidy, Cancer Res., 1995, 55, 2090 CAS.
  4. (a) S. Neidle and M. Waring, Molecular Aspects of Anticancer Drug-DNA Interactions, Macmillan Press, London, 1993 Search PubMed; (b) W. B. Pratt, R. W. Ruddon, W. D. Ensminger and J. Maybaum, The Anticancer Drugs, Oxford University Press, London, 1994 Search PubMed; (c) G. Capranico, E. Butelli and F. Zunino, Cancer Res., 1995, 55, 312 CAS.
  5. (a) C. Cullinane, S. M. Cutts, A. van Rosmalen and D. R. Phillips, Nucleic Acids Res., 1994, 22, 2296 CAS; (b) C. Cullinane and D. R. Phillips, Biochemistry, 1994, 33, 6207 CrossRef CAS.
  6. F. Leng, R. Savkur, I. Fokt, T. Przewloka, W. Priebe and J. B. Chaires, J. Am. Chem. Soc., 1996, 118, 4731 CrossRef CAS.
  7. B. Pullman, Anti-Cancer Drug Des., 1991, 7, 95 Search PubMed.
  8. (a) J. M. Neumann, J. A. Cavailles, M. Herve, S. Tran-Dinh, B. Langlois d'Estaintot, T. Huynh-Dinh and J. Igolen, FEBS Lett., 1985, 182, 360 CrossRef CAS; (b) J. B. Chaires, K. R. Fox, J. E. Herrera, M. Britt and M. J. Waring, Biochemistry, 1987, 26, 8227 CrossRef CAS; (c) V. Rizzo, C. Battistini, A. Vigevani, N. Sacchi, G. Rozzano, F. Arcamone, A. Garbesi, F. P. Colonna, M. Capobianco and L. Tondelli, J. Mol. Recognit., 1989, 2, 132 CAS.
  9. (a) E. Ragg, R. Mondelli, C. Battistini, A. Garbesi and F. P. Colonna, FEBS Lett., 1988, 236, 231 CrossRef CAS; (b) R. Bortolini, S. Mazzini, R. Mondelli, E. Ragg, C. Ulbricht, S. Vioglio and S. Penco, Appl. Magn. Reson., 1994, 7, 71 CrossRef CAS.
  10. (a) A. H. J. Wang, G. Ughetto, G. J. Quigley and A. Rich, Biochemistry, 1987, 26, 1152 CrossRef CAS; (b) M. H. Moore, W. N. Hunter, B. Langlois d'Estaintot and O. Kennard, J. Mol. Biol., 1989, 206, 693 CrossRef CAS; (c) A. Frederick, L. D. Williams, G. Ughetto, G. A. van der Marel, J. H. van Boom, A. Rich and A. H. J. Wang, Biochemistry, 1990, 29, 2538 CrossRef; (d) Y. G. Gao and A. H. J. Wang, Anti-Cancer Drug Des., 1991, 6, 137 Search PubMed.
  11. (a) M. Cirilli, F. Bachechi, G. Ughetto, F. P. Colonna and M. L. Capobianco, J. Mol. Biol., 1992, 230, 878 CrossRef CAS; (b) Y. G. Gao and A. H. J. Wang, J. Biomol. Struct. Dyn., 1995, 13, 103 Search PubMed.
  12. (a) C. Odefey, J. Westendorf, T. Dieckmann and H. Oschkinat, Chem. Biol. Interact., 1992, 85, 117 CrossRef CAS; (b) J. Igarashi and M. Sunagawa, Bioorg. Med. Chem. Lett., 1995, 5, 2923 CrossRef CAS.
  13. H. Chen and D. J. Patel, J. Am. Chem. Soc., 1995, 117, 5901 CrossRef CAS.
  14. (a) L. Braunschweiler and R. R. Ernst, J. Magn. Reson., 1983, 53, 521 CAS; (b) A. Bax and D. G. Davis, J. Magn. Reson., 1985, 65, 355 CAS; (c) V. Sklenàr and A. Bax, J. Magn. Reson., 1987, 74, 469 CAS; (d) A. Bax, R. H. Griffey and B. L. Hawkins, J. Magn. Reson., 1983, 55, 301 CAS; (e) M. R. Bendall, D. T. Pegg and D. M. Doddrell, J. Magn. Reson., 1983, 52, 81 CAS.
  15. S. J. Weiner, P. A. Kollman, D. A. Case, U. C. Singh, C. Ghio, G. Alagona, S. Jr. Profeta and P. Weiner, J. Am. Chem. Soc., 1984, 106, 756.
  16. (a) J. W. Lown, C. C. Hanstock, R. C. Bleackley, J. L. Imbach, B. Rayner and J. J. Vasseur, Nucleic Acids Res., 1984, 12, 2519 CAS; (b) L. Nilsson, G. M. Clore, A. M. Gronenborn, A. T. Brünger and M. Karplus, J. Mol. Biol., 1986, 188, 455 CAS; (c) M. Delepierre, T. Huynh Dihn and B. P. Proques, Biopolymers, 1989, 28, 2115 CAS.
  17. (a) D. G. Gorenstein, Phosphorus-31 NMR. Principles and Applications, Academic Press, New York, 1984 Search PubMed; (b) D. G. Gorenstein, Chem. Rev., 1994, 94, 1315 CrossRef CAS and references cited therein.
  18. K. Wutrich, NMR of Proteins and Nucleic Acids, Wiley, New York, 1986 Search PubMed.
  19. (a) R. Mondelli, E. Ragg, G. Fronza and A. Arnone, J. Chem. Soc., Perkin Trans. 2, 1987, 15 RSC; (b) R. Mondelli, E. Ragg and G. Fronza, J. Chem. Soc., Perkin Trans. 2, 1987, 27 RSC.
  20. W. Saenger, Principles of Nucleic Acid Structure, Springer-Verlag, New York, 1984 and references cited therein Search PubMed.
Click here to see how this site uses Cookies. View our privacy policy here.